Participants’ experiences, feedback and satisfaction with screening (n=75)
| N | (%) | ||
| Experience and feedback on pharmacist-delivered screening | |||
| Person who initiated the conversation about screening between participant and pharmacist | Another participant in the project | 1 | (1.3) |
| Pharmacist | 51 | (68.0) | |
| Pharmacy staff | 2 | (2.7) | |
| Acquaintance | 13 | (17.3) | |
| Social media | 8 | (10.7) | |
| Clarity of pharmacist’s explanation of risk of developing diabetes and CVD | Very clear | 59 | (78.7) |
| Clear enough | 14 | (18.7) | |
| Some parts clear | 1 | (1.3) | |
| Generally unclear | 1 | (1.3) | |
| Depth of pharmacist’s exploration of possible lifestyle causes of increased diabetes and CVD risks | Very comprehensive | 57 | (76.0) |
| Discussed several issues | 13 | (17.3) | |
| Discussed only one issue | 7 | (9.3) | |
| Steps undertaken following screening | The pharmacist provided you with a written report of your results | 67 | (89.3) |
| The pharmacist made sure that you understood everything | 69 | (94.5) | |
| The pharmacist clearly stated when the physician follow-up was required | 24 | (33.8) | |
| Quality of the testing carried out in pharmacy | Excellent | 53 | (70.7) |
| Above average | 12 | (16.0) | |
| Average | 6 | (8.0) | |
| Slightly below average | 4 | (5.3) | |
| Perceived length of the diabetes and CVD risk screening process | Much too long | 2 | (2.7) |
| A little long | 12 | (16.0) | |
| About right | 58 | (77.3) | |
| A little short | 3 | (4.0) | |
| Satisfaction with the pharmacist-delivered screening | |||
| Satisfaction with health risk assessment | Very satisfied | 43 | (58.9) |
| Satisfied | 26 | (35.6) | |
| Average | 3 | (4.1) | |
| Dissatisfied | 1 | (1.4) | |
| Satisfaction with the quality of advice provided in the pharmacy | Very satisfied | 40 | (54.1) |
| Satisfied | 27 | (36.5) | |
| Average | 5 | (6.8) | |
| Dissatisfied | 2 | (2.7) | |
| Willingness to pay for the future pharmacist-delivered screening service | |||
| Yes | 60 | (80.0) | |
| Acceptable amount to be paid | ≤50 AED (≤USD 13.6*) | 34 | (56.7) |
| 51–100 AED (USD 13.6–27.2*) | 19 | (31.7) | |
| 101–150 AED (USD 27.2–48.8*) | 6 | (10.0) | |
| >150 AED (>USD 48.8*) | 1 | (1.7) | |
| Reasons for unwillingness to pay for future pharmacist-delivered screening service | Cannot afford it | 2 | (14.3) |
| Does not think it is worth it | 3 | (21.4) | |
| Thinks it should be free | 3 | (21.4) | |
| Other | 6 | (42.9) | |
CVD, cardiovascular disease.